@article{oai:yamagata.repo.nii.ac.jp:00003481,
 author = {柴田,  健一 and 鈴木,  明彦 and 渡邊,  利広 and 高須,  直樹 and 平井,  一郎 and 木村,  理},
 issue = {2},
 journal = {山形大学紀要. 医学 : 山形医学 = Bulletin of the Yamagata University. Medical science : Yamagata medical journal},
 month = {Aug},
 note = {論文(Article), Background: Epithelial-Mesenchymal Transition (EMT) plays an important role in cancer progression and metastasis. We investigated the expression of two EMT-related molecules, ZEB-1 and E-cadherin, in invasive ductal breast carcinoma and evaluated their association with clinicopathological parameters and recurrence-free survival.
Methods: We evaluated the expression of ZEB-1 and E-cadherin in 116 patients of Stage I, II, and III primary invasive ductal breast carcinoma (mean age, 58.5 years, male: female = 0:116) using immunohistochemistry.
Results: Of the 116 patients, 51 (44%) had Stage I, 58 (50%) had Stage II,　and 7 (6%) had Stage III tumors. Thirty seven patients (32%) had lymph node metastasis. One hundred and one patients (87%) had ER positive tumors, and 20 patients (17%) had HER2 positive tumors. Positive ZEB-1 expression was observed in the tumors of 66 patients (57%), but it was not significantly associated with clinicopathological parameters. Reduced E-cadherin expression was observed in the tumors of 34 patients (29%). It was significantly associated with negative estrogen receptor expression. Patients with a positive ZEB-1 and / or reduced E-cadherin had a poorer outcome than the other patients in terms of recurrence-free survival.
Conclusion: ZEB-1 and E-cadherin expression may predict recurrence-free survival in patients with invasive ductal breast carcinoma.},
 pages = {61--69},
 title = {ZEB-1 and E-cadherin expression may predict recurrence-free survival in patients with invasive ductal breast carcinoma},
 volume = {33},
 year = {2015}
}